OCRELIZUMAB

Ocrelizumab Overview

Ocrelizumab (brand name Ocrevus) is a prescription medicine given by intravenous (IV) infusion to treat adults with relapsing or primary progressive forms of multiple sclerosis (MS). Neurologists prescribe this antibody treatment to reduce relapses and slow down physical disability progression.

Key Facts Summary:

What Is Ocrelizumab and How Does It Work?

Ocrelizumab is a single active ingredient medicine called a humanized monoclonal antibody.

Mechanism of Action

Multiple sclerosis is an autoimmune disease where the body’s immune system mistakenly attacks the protective myelin sheath around axons in the central nervous system (brain and spinal cord). Specific immune cells called pre-B and mature B lymphocytes play a central role in driving this disease activity. These B cells express a distinct cell-surface antigen called the CD20 protein.

Ocrelizumab works by binding directly to the CD20 cell-surface antigen expressed on circulating B cells. Upon binding, it induces antibody-dependent cellular cytolysis and complement-mediated lysis, depleting CD20-positive B cells from the peripheral circulation. By reducing these autoreactive B cells while sparing stem cells and plasma cells, the medicine prevents B-cell-mediated immune attacks against the central nervous system, thereby reducing MS relapses and slowing physical disability progression.

Is Ocrelizumab FDA Approved?

Yes, Ocrelizumab is officially approved by the United States Food and Drug Administration. It was the first disease-modifying therapy approved to treat primary progressive multiple sclerosis.

What Is Ocrelizumab Used For?

• Relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
• Primary progressive multiple sclerosis (PPMS) in adults.
• Relapsing-remitting MS in pediatric patients 10 years of age and older weighing at least 25 kg.

Before Taking Ocrelizumab: Contraindications and Precautions

Because Ocrelizumab selectively depletes B cells, your medical team will perform thorough baseline blood screenings to verify immune function and rule out latent viral infections.

Who Should Not Take Ocrelizumab?

• Anyone with an active Hepatitis B virus (HBV) infection (e.g., HBsAg positive).
• Anyone with a history of life-threatening infusion or injection reactions to Ocrelizumab.

Ocrelizumab, Pregnancy and Fertility

Discuss pregnancy plans with your doctor. Ocrelizumab crosses the placenta and can cause fetal B-cell depletion and lymphopenia in newborn infants. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final infusion. It is unknown if Ocrelizumab passes into human breast milk. Discuss the risks and benefits of breastfeeding with your doctor.

Tell Your Doctor Before Taking Ocrelizumab

• Disclose any active infections or a history of recurrent bacterial, viral, or fungal infections.
• Inform your provider if you have ever had Hepatitis B or are a carrier of the virus.
• Share if you have a history of inflammatory bowel disease, immune-mediated colitis, or severe gastrointestinal issues.
• Provide a complete list of all vaccines you have received or plan to receive. Live-attenuated vaccines must be given at least 4 weeks before starting Ocrelizumab.

Ocrelizumab Dosage and Administration

Ocrelizumab is administered in a medical facility by trained healthcare professionals who can monitor vital signs and manage potential hypersensitivity reactions.

Standard Ocrelizumab Dosing

• Initial Dose: The first treatment is split into two 300 mg IV infusions given 2 weeks apart (Days 1 and 15).
• Maintenance Dose: Subsequent doses are administered as a single 600 mg IV infusion once every 6 months.
• Infusion Duration: Maintenance infusions take between 2 and 4 hours depending on the prescribed infusion rate and individual tolerability.

How Ocrelizumab Is Administered

• Pre-medications: Approximately 30 to 60 minutes prior to each infusion, administer 100 mg IV methylprednisolone (or an equivalent corticosteroid) and an oral or IV antihistamine (e.g., diphenhydramine) to reduce the incidence and severity of infusion-related reactions. An antipyretic (e.g., acetaminophen) may also be administered.
• The diluted solution is infused intravenously via a dedicated line with a 0.2 to 0.22 micron in-line filter.
• Patients must be observed closely during the infusion and for at least 1 hour post-infusion.

Ocrelizumab Clinical Efficacy and Research

FDA approval of Ocrelizumab was supported by three pivotal Phase 3 trials: OPERA I and OPERA II in relapsing MS, and ORATORIO in primary progressive MS. In OPERA I and II, Ocrelizumab significantly reduced annualized relapse rates by nearly 50% compared to subcutaneous interferon beta-1a over 96 weeks. MRI endpoints demonstrated a near-complete suppression of new gadolinium-enhancing T1 lesions and new/enlarging T2 lesions. In the ORATORIO trial, Ocrelizumab significantly reduced the risk of 12-week and 24-week confirmed disability progression compared to placebo in PPMS patients.

Ocrelizumab Side Effects and Safety Profile

While Ocrelizumab provides robust disease modification, peripheral B-cell depletion raises susceptibility to opportunistic infections and acute infusion-related events.

Common Ocrelizumab Side Effects

• Upper respiratory tract infections (nasopharyngitis, sinusitis).
• Infusion-related reactions (pruritus, rash, flushing, fever, fatigue).
• Skin infections (e.g., cellulitis).
• Lower respiratory tract infections (bronchitis).
• Herpes virus infections (herpes simplex, herpes zoster/shingles).

Serious Ocrelizumab Adverse Events

• Infusion-Related Reactions: Severe, life-threatening systemic hypersensitivity reactions involving bronchospasm, hypoxia, anaphylaxis, or hypotension.
• Infections: Serious viral, bacterial, or fungal infections; reactivation of latent Hepatitis B virus leading to fulminant hepatitis and liver failure.
• Progressive Multifocal Leukoencephalopathy (PML): Opportunistic John Cunningham (JC) virus brain infection causing severe neurological disability or death.
• Decreased Immunoglobulins: Progressive reduction in serum IgG, IgA, and IgM levels with chronic dosing.
• Immune-Mediated Colitis: Severe intestinal inflammation presenting as persistent diarrhea, abdominal pain, or gastrointestinal bleeding.

Managing Ocrelizumab Side Effects

Pre-medicating prior to each dose minimizes acute infusion responses. If mild-to-moderate infusion reactions occur (such as flushing or throat irritation), slow or temporarily interrupt the infusion. If signs of severe hypersensitivity or anaphylaxis appear, stop the infusion immediately and administer emergency supportive care. Promptly evaluate fever, chills, persistent cough, or localized pain for underlying infection.

Ocrelizumab Drug Interactions and What to Avoid

Co-administration with other immunomodulatory therapies or administration of live vaccines requires strict clinical timing.

Ocrelizumab Drug-Drug Interactions

• Immunosuppressive Medications (Corticosteroids, Methotrexate, Anti-TNF agents, DMARDs): Concomitant use or sequential administration without an adequate wash-out period increases the cumulative risk of severe systemic infection.
• Live Vaccines (e.g., MMR, Varicella, Yellow Fever): Live-attenuated vaccines are contraindicated during treatment and until peripheral B-cell repletion has occurred due to reduced humoral immune response and risk of vaccine-derived infection.

Ocrelizumab, Food and Alcohol

• Food intake does not interfere with intravenous administration.
• Maintain adequate oral hydration prior to infusion to support venous access and prevent post-infusion headache.

Ocrelizumab Missed Dose, Overdose and Storage

Maintaining the bi-annual dosing schedule preserves B-cell suppression and prevents breakthrough neuroinflammation.

Missed Dose of Ocrelizumab

If a scheduled 6-month infusion is missed, administer the dose as soon as possible. Do not wait until the next planned dose interval. Reset the subsequent 6-month dosing schedule from the date of the newly administered dose.

Ocrelizumab Overdose and Emergency

Because Ocrelizumab is prepared and administered solely by healthcare professionals using single-dose vials, accidental overdose is unlikely. In case of dosing error, monitor the patient for exaggerated B-cell depletion and infection.

How to Store Ocrelizumab

• Vials must be stored refrigerated between 36°F and 46°F (2°C and 8°C) in the original carton to protect from light.
• Do not freeze or shake the solution.

Ocrelizumab Patient Management and Monitoring

Pre-treatment screening and ongoing clinical laboratory tracking ensure patient safety during prolonged B-cell depletion.

Tests Before Starting Ocrelizumab

• Hepatitis B virus screening (HBsAg and total anti-HBc testing).
• Baseline serum immunoglobulin levels (IgG, IgA, IgM).
• Liver function tests (ALT, AST, total bilirubin).
• Assessment of immunization status and completion of required live vaccines at least 4 weeks prior.

Monitoring During Ocrelizumab Treatment

• Observation for infusion-related reactions during infusion and for at least 1 hour post-infusion.
• Screening for signs and symptoms of active infection prior to each dose.
• Periodic serum immunoglobulin testing (IgG, IgA, IgM).
• Monitoring for neurological symptoms indicative of PML or gastrointestinal symptoms indicative of immune-mediated colitis.

Ocrelizumab Do’s and Don’ts

• DO complete all baseline Hepatitis B and immunoglobulin blood screenings prior to your first dose.
• DO report fever, chills, cough, or painful rash to your physician immediately.
• DON’T receive live-attenuated vaccines during therapy or prior to B-cell recovery.
• DON’T skip or delay your scheduled 6-month maintenance infusions.

Frequently Asked Questions

References

• U.S. FDA prescribing information for Ocrevus (Ocrelizumab) injection
• U.S. FDA Drugs@FDA drug approval overview (Application No. 761053)
• OPERA I, OPERA II, and ORATORIO Phase 3 Clinical Trial Results in Multiple Sclerosis

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.